These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 4745832)
41. Effects of cyclazocine and scopolamine on swim-to-platform performance in rats. Buckton G; Zibrowski EM; Vanderwolf CH Brain Res; 2001 Dec; 922(2):229-33. PubMed ID: 11743954 [TBL] [Abstract][Full Text] [Related]
42. ANALGESIC EFFECTS IN MONKEYS OF MORPHINE, NALORPHINE, AND A BENZOMORPHAN NARCOTIC ANTAGONIST. WEISS B; LATIES VG J Pharmacol Exp Ther; 1964 Feb; 143():169-73. PubMed ID: 14163989 [No Abstract] [Full Text] [Related]
43. Effects of cyclazocine on cocaine self-administration in rats. Glick SD; Visker KE; Maisonneuve IM Eur J Pharmacol; 1998 Sep; 357(1):9-14. PubMed ID: 9788768 [TBL] [Abstract][Full Text] [Related]
44. Potent long-acting antagonists of the 9,9-dialkylbenzomorphan series. Janssen PA Adv Biochem Psychopharmacol; 1973; 8(0):109-11. PubMed ID: 4795015 [No Abstract] [Full Text] [Related]
45. A test for antinociceptive activity of narcotic and narcotic antagonist analgesics in the guinea pig. Teiger DG J Pharmacol Exp Ther; 1976 May; 197(2):311-6. PubMed ID: 5596 [TBL] [Abstract][Full Text] [Related]
46. Biodegradable polymers in controlled drug delivery. Heller J Crit Rev Ther Drug Carrier Syst; 1984; 1(1):39-90. PubMed ID: 6400195 [TBL] [Abstract][Full Text] [Related]
47. Effects of narcotic agonists and antagonists on schedule-induced water and morphine ingestion. Leander JD; McMillan DE; Harris LS J Pharmacol Exp Ther; 1975 Nov; 195(2):271-8. PubMed ID: 1237618 [TBL] [Abstract][Full Text] [Related]
49. The effect of morphine, nalorphine, naloxone, pentazocine, cyclazocine and oxotremorine on the synthesis and release of acetylcholine by mouse cerebral cortex slices in vitro. Howes JF; Harris LS; Dewey WL Arch Int Pharmacodyn Ther; 1970 Apr; 184(2):267-76. PubMed ID: 5453231 [No Abstract] [Full Text] [Related]
53. On the ability of narcotic antagonists to produce the narcotic cue. Colpaert FC; Niemegeers CJ; Janssen PA J Pharmacol Exp Ther; 1976 Apr; 197(1):180-7. PubMed ID: 4610 [TBL] [Abstract][Full Text] [Related]
54. Development of drug delivery systems for use in treatment of narcotic addiction. Sharon AC; Wise DL NIDA Res Monogr; 1981; 28():194-213. PubMed ID: 6791005 [TBL] [Abstract][Full Text] [Related]
55. Further characterization of the three-choice morphine, cyclazocine and saline discrimination paradigm: opioids with agonist and antagonist properties. White JM; Holtzman SG J Pharmacol Exp Ther; 1983 Jan; 224(1):95-9. PubMed ID: 6336785 [TBL] [Abstract][Full Text] [Related]
56. In brief: a naloxone auto-injector (Evzio). Med Lett Drugs Ther; 2014 Jun; 56(1444):45. PubMed ID: 24933086 [No Abstract] [Full Text] [Related]
57. Cyclazocine in the treatment of narcotic addiction. Jaffe JH Curr Psychiatr Ther; 1967; 7():147-56. PubMed ID: 4860298 [No Abstract] [Full Text] [Related]